Corporate information

Pipeline 

• Alitretinoin belongs to the well studied family of retinoids and is targeted at patients with severe chronic hand eczema who do not respond to topical corticosteroids. Alitretinoin is marketed in the United Kingdom, Denmark, France and Germany and is approved in Austria, Belgium, Canada, Finland, Luxemburg, the Netherlands, Spain and Switzerland under the trade name Toctino®. Alitretinoin has been recommended for approval in additional 16 European countries.
• Ceftobiprole is the first approved broad-spectrum anti-MRSA antibiotic belonging to the cephalosporin class. Ceftobiprole is marketed in Canada under the brand name ZEFTERA™ for the treatment of complicated skin and skin structure infections (cSSSI), including non-limb threatening diabetic foot infections without concomitant osteomyelitis; and Switzerland (Zevtera™) for the treatment of complicated skin and and soft tissue infections (cSSTI) including diabetic foot infections (DFI) without concomitant osteomyelitis. Marketing applications for ceftobiprole are submitted in the EU and several other countries.  
• Isavuconazole, a novel broad-spectrum antifungal, is being developed for the treatment of severe invasive fungal infections and has the potential to become the best-in-class azole. The water-soluble compound can be administered intravenously or orally. The investigational drug has received fast track status from the FDA and is in clinical phase III development. 
• Preclinical programs: Basilea pursues research programs in lead optimization as well as early stages of discovery. The most advanced preclinical development compounds are BAL30072 and BAL27862. The novel antibiotic BAL30072 is active against some of the most difficult-to-treat multi-resistant Gram-negative bacteria, such as Pseudomonas and Acinetobacter. BAL27862 is a novel anti-cancer compound with activity against a broad range of tumor types, including those unresponsive to standard therapeutics.

History